Tubal origin of ovarian low-grade serous carcinoma.

Ovarian low-grade serous carcinomas are thought to evolve in a stepwise fashion from ovarian epithelial inclusions, cystadenomas, and borderline tumors. The current study was designed to gain insight into the origins of low-grade serous carcinomas (tubal versus ovarian) by comparatively evaluating the morphologic (secretory and ciliated cell distribution) and immunophenotypic (using antibodies to PAX8, tubulin, calretinin, and Ki67) attributes of its putative precursor lesions, the normal tubal epithelium, and the overt malignancy. A total of 226 adnexal tissues from 178 patients were studied, including 98 adnexae removed for non-neoplastic indications, 48 serous cystadenomas, 42 serous borderline tumors, and 38 low-grade serous carcinomas. Normal distal tubal epithelium comprised an admixture of PAX8+/tubulin− secretory cells and PAX8−/tubulin+ ciliated cells with a proliferative index of ∼3%. The vast majority of ovarian surface epithelia displayed a mesothelial phenotype (calretinin+/PAX8−/tubulin−) and low proliferative index (0% (12 per 1000)), although 4% of cases also displayed foci with tubal phenotype (calretinin−/PAX8+/tubulin+). In contrast, most (78%) of the ovarian epithelial inclusions displayed a tubal phenotype and had a significantly higher proliferative index (1%) than ovarian surface epithelium, indicating that in most cases, the ovarian surface epithelium and ovarian epithelial inclusions are of different lineages. There was a progressive decrease in the population of ciliated cells, as evidenced by increasing secretory/ciliated cell ratio, from ovarian epithelial inclusions/cystadenomas to borderline tumors to low-grade serous carcinoma, indicating that the latter is a clonal expansion of secretory cells. Overall, the findings make a strong argument that the ovarian epithelial inclusions with a tubal phenotype is likely derived from fallopian tube through an intraovarian endosalpingiosis rather than through Mullerian metaplasia from ovarian surface epithelium. Genetic and molecular studies are needed to further confirm this finding as tubal origination of ovarian serous cancers will have a significant impact on ovarian cancer prevention and management.

[1]  Fathalla Mf.  Incessant ovulation--a factor in ovarian neoplasia? [letter] , 1971 .

[2]  R. Drapkin,et al.  PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma , 2010, The American journal of surgical pathology.

[3]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[4]  Hsin-Yang Li,et al.  Oestrogen‐induced epithelial–mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis , 2010, The Journal of pathology.

[5]  B. Kong,et al.  Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis , 2012, Journal of Hematology & Oncology.

[6]  R. Kurman,et al.  Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. , 1996, The American journal of surgical pathology.

[7]  C. Crum.  Intercepting pelvic cancer in the distal fallopian tube: Theories and realities , 2009, Molecular oncology.

[8]  Ie-Ming Shih,et al.  Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[9]  Ross S Berkowitz,et al.  Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Joan G. Jones,et al.  Expression of Calretinin in Human Ovary, Testis, and Ovarian Sex Cord-Stromal Tumors , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[11]  Russell Vang,et al.  Fallopian tube precursors of ovarian low‐ and high‐grade serous neoplasms , 2013, Histopathology.

[12]  R. Scully.  Pathology of ovarian cancer precursors , 1995, Journal of cellular biochemistry. Supplement.

[13]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[14]  Chung-Liang Ho,et al.  Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors , 2004, Cancer Research.

[15]  I. Shih,et al.  Papillary Tubal Hyperplasia: The Putative Precursor of Ovarian Atypical Proliferative (Borderline) Serous Tumors, Noninvasive Implants, and Endosalpingiosis , 2011, The American journal of surgical pathology.

[16]  N. Auersperg.  The Origin of Ovarian Carcinomas: A Unifying Hypothesis , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[17]  F. McKeon,et al.  Cellular origin of Barrett's esophagus: controversy and therapeutic implications. , 2012, Gastroenterology.

[18]  R. Drapkin,et al.  STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. , 2011, Frontiers in bioscience.

[19]  J. McKenney,et al.  Ovarian Serous Tumors of Low Malignant Potential (Borderline Tumors): Outcome-Based Study of 276 Patients With Long-Term (≥5-Year) Follow-Up , 2005, The American journal of surgical pathology.

[20]  L. Mazzucchelli,et al.  Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high‐grade carcinomas support different pathogenetic pathways , 2005, The Journal of pathology.

[21]  E. Winterhager,et al.  Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. , 2007, Endocrinology.

[22]  Luis Chiriboga,et al.  Expression of Pax8 as a Useful Marker in Distinguishing Ovarian Carcinomas From Mammary Carcinomas , 2008, The American journal of surgical pathology.

[23]  G. Ning,et al.  Fallopian Tube Correlates of Ovarian Serous Borderline Tumors , 2011, The American journal of surgical pathology.

[24]  J. Dungan.  Tubal origin of “ovarian” low-grade serous carcinoma , 2012 .

[25]  M F Fathalla,et al.  Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.

[26]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[27]  K. Münger,et al.  A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer , 2012, Proceedings of the National Academy of Sciences.

[28]  R. Drapkin,et al.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Thigpen.  Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention , 2009 .

[30]  Carl Virtanen,et al.  Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. , 2010, Gynecologic oncology.

[31]  A. Berchuck,et al.  K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary. , 2001, Gynecologic oncology.

[32]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[33]  G. Enikolopov,et al.  Ovarian surface epithelium at the junction area contains cancer-prone stem cell niche , 2013, Nature.

[34]  Rochelle L. Garcia,et al.  Unexpected Gynecologic Neoplasms in Patients With Proven or Suspected BRCA-1 or -2 Mutations: Implications for Gross Examination, Cytology, and Clinical Follow-up , 2002, The American journal of surgical pathology.

[35]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[36]  Khek Yu Ho,et al.  Residual Embryonic Cells as Precursors of a Barrett's-like Metaplasia , 2011, Cell.

[37]  B. Crawford,et al.  Multistep Level Sections to Detect Occult Fallopian Tube Carcinoma in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations: Implications for Defining an Optimal Specimen Dissection Protocol , 2009, The American journal of surgical pathology.

[38]  M. Wells,et al.  p53 protein expression in putative precursor lesions of epithelial ovarian cancer , 1995, Histopathology.

[39]  F. McKeon,et al.  A novel blueprint for ‘top down’ differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia , 2013, The Journal of pathology.

[40]  Olufunmilayo I. Olopade,et al.  Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation , 2006 .

[41]  N. Bowen,et al.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. , 2007, Gynecologic oncology.

[42]  C. Gilks,et al.  The origin of ovarian carcinomas: a developmental view. , 2008, Gynecologic oncology.

[43]  N. Ordóñez.  Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. , 1998, The American journal of surgical pathology.

[44]  R. Attanoos,et al.  Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum , 2002, Histopathology.

[45]  Kathleen R. Cho,et al.  Surface Epithelial Tumors of the Ovary , 2011 .

[46]  R. Kurman,et al.  The Fallopian Tube-Peritoneal Junction: A Potential Site of Carcinogenesis , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[47]  R. Drapkin,et al.  Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[48]  F. McKeon,et al.  High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression , 2010, Modern Pathology.

[49]  Jason D. Wright,et al.  Pax8: A marker for carcinoma of Müllerian origin in serous effusions , 2011, Diagnostic Cytopathology.

[50]  G. Ning,et al.  Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube , 2010, The Journal of pathology.

[51]  Adam B. Olshen,et al.  Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma , 2010, PloS one.

[52]  B. Ruggeri,et al.  PAX genes: roles in development, pathophysiology, and cancer. , 2007, Biochemical pharmacology.

[53]  C. Crum,et al.  Precursors to pelvic serous carcinoma and their clinical implications. , 2009, Gynecologic oncology.

[54]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[55]  A. Godwin,et al.  Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. , 1992, Journal of the National Cancer Institute.

[56]  J. Marto,et al.  Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis , 2009, Oncogene.

[57]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[58]  J. Foekens,et al.  Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. , 1994, The American journal of pathology.

[59]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[60]  Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective , 2009 .

[61]  U. Löhrs,et al.  KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. , 2006, Gynecologic oncology.

[62]  Michael T Deavers,et al.  Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.

[63]  J. McKenney,et al.  Patterns of Stromal Invasion in Ovarian Serous Tumors of Low Malignant Potential (Borderline Tumors): A Reevaluation of the Concept of Stromal Microinvasion , 2006, The American journal of surgical pathology.

[64]  K. Hatch,et al.  Secretory cell expansion with aging: risk for pelvic serous carcinogenesis. , 2013, Gynecologic oncology.

[65]  G. Ning,et al.  Through the glass darkly: intraepithelial neoplasia, top‐down differentiation, and the road to ovarian cancer , 2013, The Journal of pathology.

[66]  R. Drapkin,et al.  Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer , 2007, Clinical Medicine & Research.

[67]  E. Kohn,et al.  Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. , 2004, Human pathology.

[68]  A. Flanagan,et al.  In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.

[69]  N. Ordóñez.  The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study , 2006, Modern Pathology.

[70]  M. Sherman,et al.  Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. , 2004, Human pathology.

[71]  L. Dubeau,et al.  The cell of origin of ovarian epithelial tumours. , 2008, The Lancet. Oncology.

[72]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[73]  M. Sherman,et al.  Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. , 1996, The American journal of surgical pathology.

[74]  U. Löhrs,et al.  In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential , 1999, Virchows Archiv.

[75]  C. Landen,et al.  The role of the fallopian tube in the origin of ovarian cancer. , 2013, American journal of obstetrics and gynecology.